SG 152/24
Californian prohibition will phase out DEHP and other plasticizers in intravenous solution containers by 2030 and in intravenous tubing by 2035.
On September 25, 2024, the governor of California signed AB 2300 (Chapter 562) into law, prohibiting Di-(2-ethylhexyl) phthalate (DEHP) in intravenous solution containers (IV bags) and IV tubing. The law makes California the first US jurisdiction to restrict ortho-phthalates in medical devices.
DEHP is an ortho-phthalate, which is commonly added to plastic materials, particularly polyvinyl chloride (PVC), as a plasticizer to increase the material’s flexibility. Exposure to DEHP has been associated with various adverse health effects, such as endocrine disruption, harm to the reproductive system and cancer.
The law provides several terms and their definitions, including but not limited to the following:
- ‘Intravenous solution containers’ means a container used to house medicine, fluid or nutrition therapy that is intravenously administered to patients in a hospital, outpatient or other health care facility
- ‘Intravenous tubing‘ means any tubing used to intravenously administer fluids, medication or nutrients directly to an adult, child or infant
- ‘Ortho-phthalates’ means a class of chemicals that are esters of ortho-phthalic acid, including all of the substances listed in Table 2
Highlights of AB 2300 are summarized in Table 1.
Substance | Scope | Requirement | Effective date | ||||
DEHP | Intravenous solution containers (IV bags) | Prohibited if intentionally added1,2 < 0.1%, if unintentionally added | January 1, 20303 | ||||
DEHP | Intravenous tubing | Prohibited if intentionally added1,2 < 0.1%, if unintentionally added | January 1, 2035 |
Table 1
1 DEHP shall not be replaced with other ortho-phthalates
2 Exempts human blood collection and storage bags as well as apheresis and cell therapy blood kits and bags, including integral tubing
3 Effective date of January 1, 2032 applies to manufacturers awaiting US Food and Drug Administration (FDA) approval of DEHP-free IV bags or lacking equipment to manufacture DEHP-free IV bags if manufacturer meets the following requirements (1) manufacturer to inform California customers by July 1, 2025, about its development of DEHP-free IV bags meeting requirements of this law, and (2) manufacturer to provide notice to customers and post to its website by January 1, 2028, that original deadline of January 1, 2030, cannot be met
Ortho-phthalates as listed under CA AB 2300 are specified in Table 2.
Entry | Abbreviation | Ortho-phthalate | CAS |
1 | BBP | Benzyl-butyl phthalate | 85-68-7 |
2 | DBP | Dibutyl phthalate | 84-74-2 |
3 | DCHP | Dicyclohexyl phthalate | 84-61-7 |
4 | DEHP | Di-(2-ethylhexyl) phthalate | 117-81-7 |
5 | DEP | Diethyl phthalate | 84-66-2 |
6 | DIBP | Di-isobutyl phthalate | 84-69-5 |
7 | DIDP | Di-isodecyl phthalate | 26761-40-0 |
8 | DINP | Di-isononyl phthalate | 28553-12-0 |
9 | DnHP | Di-n-hexyl phthalate | 84-75-3 |
10 | DNOP | Di-n-octyl phthalate | 117-84-0 |
11 | DnPP | Di-n-pentyl phthalate | 131-18-0 |
12 | DIHP | Diisoheptyl phthalate | 71888-89-6 |
Table 2
From the simplicity of a syringe to the complexity of a pacemaker, medical devices are heavily regulated and must meet market-specific quality, safety, and performance standards. At SGS, we help you bring medical devices to market safely and efficiently. Our experts deliver a wide range of standard and non-standard tests on medical devices and certify them through our notified bodies. Contact us for more information or visit our website. In the end, it’s only trusted because it’s tested.
© SGS Société Générale de Surveillance SA. This publication or website is a property of SGS Société Générale de Surveillance SA. All contents including website designs, text, and graphics contained herein are owned by or licensed to SGS Société Générale de Surveillance SA. The information provided is for technical and general information purposes only and offers no legal advice. The information is no substitute for professional legal advice to ensure compliance with the applicable laws and regulations. All information is provided in good faith “as is”, and SGS Société Générale de Surveillance SA makes no representation or warranty of any kind, express or implied, and does not warrant that the information will be error-free or meet any particular criteria of performance or quality.
Cocoshe Building, Block B, 4th Floor,
Street No. B28a, Agostinho Neto Close, Airport Residential Area,
Accra, Ghana